deltatrials
Temporarily Not Available EXPANDED_ACCESS NCT00215813

Ampligen in Chronic Fatigue Syndrome

An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

Sponsor: AIM ImmunoTech Inc.

Conditions Chronic Fatigue Syndrome
Interventions Poly I: Poly C12U (Rintatolimod)
Updated 17 times since 2017 Last updated: Oct 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00215813, this observational or N/A phase trial focuses on Chronic Fatigue Syndrome and remains ongoing. Sponsored by AIM ImmunoTech Inc., it has been updated 17 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2023 · 13 months · monthly snapshot~Jul 2023 – ~May 2024 · 10 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Nov 2025 — Present [monthly]

    Temporarily Not Available

    Status: Available → Temporarily Not Available

  2. Sep 2024 — Nov 2025 [monthly]

    Available

  3. Jul 2024 — Sep 2024 [monthly]

    Available

  4. May 2024 — Jul 2024 [monthly]

    Available

  5. Jul 2023 — May 2024 [monthly]

    Available

▶ Show 12 earlier versions

  1. Jun 2022 — Jul 2023 [monthly]

    Available

  2. May 2022 — Jun 2022 [monthly]

    Available

  3. May 2021 — May 2022 [monthly]

    Available

  4. Jan 2021 — May 2021 [monthly]

    Available

  5. Nov 2020 — Jan 2021 [monthly]

    Available

  6. Feb 2020 — Nov 2020 [monthly]

    Available

  7. Jun 2019 — Feb 2020 [monthly]

    Available

  8. Sep 2018 — Jun 2019 [monthly]

    Available

  9. Aug 2018 — Sep 2018 [monthly]

    Available

    Status: Active Not Recruiting → Available · Phase: PHASE3 → None

  10. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AIM ImmunoTech Inc.
Data source: AIM ImmunoTech Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations